Celldex Therapeutics, Inc. Interest Expense
Celldex Therapeutics, Inc. (CLDX) reported Interest Expense of $927.00 thousand for the 12-month period ending 2013-12-31, per its 10-K/A filed 2016-02-25.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2016-02-25
- Celldex Therapeutics, Inc. interest expense for the quarter ending 2013-12-31 was $85.00K, a 75.78% decline year-over-year.
- Celldex Therapeutics, Inc. interest expense for the quarter ending 2013-09-30 was $13.00K, a 96.59% decline year-over-year.
- Celldex Therapeutics, Inc. interest expense for the quarter ending 2013-06-30 was $519.00K, a 26.28% increase year-over-year.
- Celldex Therapeutics, Inc. interest expense for the quarter ending 2013-03-31 was $310.00K, a 28.41% decline year-over-year.
- Celldex Therapeutics, Inc. interest expense for fiscal 2013 was $927.00K, a 41.18% decline from fiscal 2012.
- Celldex Therapeutics, Inc. interest expense for fiscal 2012 was $1.58M, a 12.25% decline from fiscal 2011.
- Celldex Therapeutics, Inc. interest expense for fiscal 2011 was $1.80M, a 34.33% increase from fiscal 2010.
- Celldex Therapeutics, Inc. interest expense for fiscal 2010 was $1.34M, a 195.80% increase from fiscal 2009.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2013-12-31 | $85.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-02-25 | $98.00K derived: sum of 2 quarters · filed 2016-02-25 | $617.00K derived: sum of 3 quarters · filed 2016-02-25 | $927.00K 10-K/A · filed 2016-02-25 |
| 2013-09-30 | $13.00K 10-Q · filed 2014-11-05 | $532.00K derived: sum of 2 quarters · filed 2014-11-05 | $842.00K 10-Q · filed 2014-11-05 | $1.19M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $519.00K 10-Q · filed 2014-08-07 | $829.00K 10-Q · filed 2014-08-07 | $1.18M derived: sum of 3 quarters · filed 2015-02-24 | $1.56M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $310.00K 10-Q · filed 2014-05-01 | $661.00K derived: sum of 2 quarters · filed 2015-02-24 | $1.04M derived: sum of 3 quarters · filed 2015-02-24 | $1.45M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $732.00K derived: sum of 2 quarters · filed 2015-02-24 | $1.14M derived: sum of 3 quarters · filed 2015-02-24 | $1.58M 10-K · filed 2015-02-24 |
| 2012-09-30 | $381.00K 10-Q · filed 2013-11-08 | $792.00K derived: sum of 2 quarters · filed 2013-11-08 | $1.23M 10-Q · filed 2013-11-08 | $1.66M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $411.00K 10-Q · filed 2013-08-06 | $844.00K 10-Q · filed 2013-08-06 | $1.28M derived: sum of 3 quarters · filed 2014-03-03 | $1.72M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $433.00K 10-Q · filed 2013-05-03 | $871.00K derived: sum of 2 quarters · filed 2014-03-03 | $1.31M derived: sum of 3 quarters · filed 2014-03-03 | $1.74M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $876.00K derived: sum of 2 quarters · filed 2014-03-03 | $1.31M derived: sum of 3 quarters · filed 2014-03-03 | $1.80M 10-K · filed 2014-03-03 |
| 2011-09-30 | $438.00K 10-Q · filed 2012-11-02 | $872.00K derived: sum of 2 quarters · filed 2012-11-02 | $1.36M 10-Q · filed 2012-11-02 | $1.69M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | $434.00K 10-Q · filed 2012-08-09 | $920.00K 10-Q · filed 2012-08-09 | $1.25M derived: sum of 3 quarters · filed 2013-03-08 | $1.59M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-03-31 | $485.00K 10-Q · filed 2012-05-04 | $820.00K derived: sum of 2 quarters · filed 2013-03-08 | $1.15M derived: sum of 3 quarters · filed 2013-03-08 | $1.49M derived: sum of 4 quarters · filed 2013-03-08 |
| 2010-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $667.00K derived: sum of 2 quarters · filed 2013-03-08 | $1.00M derived: sum of 3 quarters · filed 2013-03-08 | $1.34M 10-K · filed 2013-03-08 |
| 2010-09-30 | $332.00K 10-Q · filed 2011-11-03 | $666.00K derived: sum of 2 quarters · filed 2011-11-03 | $1.00M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $334.00K 10-Q · filed 2011-08-04 | $671.00K 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | $452.00K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |